FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Haleh Bagheri

Research Profile

Concepts & Ideas

Geographic Areas

France

Occupations

Pharmacoepidemiology

Procedures

Chemicals & Drugs

Physiology

Objects

Hospitals, University

Disorders

Activities & Behaviors

Product Surveillance, Postmarketing

Co-author Network

Publications

TOP 3
Anne Charlotte Danton; Geneviève Durrieu; Maryse Lapeyre-Mestre; François Montastruc; Haleh Bagheri; Emmanuelle Bondon-Guitton; Agnès Sommet; Jean-Louis Montastruc
Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
François Montastruc; Haleh Bagheri; Marlène Laffont; Jean-Louis Montastruc
Potentially inappropriate medications in the elderly in France: a study in community pharmacies in 2011-2012.
Guillaume Moulis; Agnès Sommet; Haleh Bagheri; Geneviève Durrieu; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Haleh Bagheri (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Anne Charlotte Danton; Geneviève Durrieu; Maryse Lapeyre-Mestre; François Montastruc; Haleh Bagheri; Emmanuelle Bondon-Guitton; Agnès Sommet; Jean-Louis Montastruc
Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France.
European journal of clinical pharmacology 2013;69(4):885-8.
2013: François Montastruc; Haleh Bagheri; Marlène Laffont; Jean-Louis Montastruc
Potentially inappropriate medications in the elderly in France: a study in community pharmacies in 2011-2012.
European journal of clinical pharmacology 2013;69(3):741-2.
2012: Guillaume Moulis; Agnès Sommet; Haleh Bagheri; Geneviève Durrieu; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.
British journal of clinical pharmacology 2012;74(1):201-4.
2012: Emmanuelle Bondon-Guitton; Haleh Bagheri; Jean-Louis Montastruc
Drug-induced gingival overgrowth: a study in the French Pharmacovigilance Database.
Journal of clinical periodontology 2012;39(6):513-8.
2012: Julien Jacquot; Jean-Louis Montastruc; Dominique Baudrin; Xavier Chastel; Mireille Gony; Haleh Bagheri
[Could we improve notification of adverse drugs reactions in hospital? Assessment of 5 years of network PharmacoMIP's activities].
Thérapie 2012;67(3):231-6.
2012: Francois Montastruc; Laurent Schmitt; Agnès Sommet; Haleh Bagheri; Emmanuelle Bondon-Guitton; Eric Bui; Geneviève Durrieu; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
European journal of clinical pharmacology 2012;68(5):767-75.
2011: Jean-Louis Montastruc; Agnès Sommet; Haleh Bagheri; Maryse Lapeyre-Mestre
Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.
British journal of clinical pharmacology 2011;72(6):905-8.
2011: Nadège Rouve; Laurent Schmitt; Norbert Telmon; Haleh Bagheri; Nicolas Franchitto; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; Atul Pathak; Daniel Rougé
Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database.
European journal of clinical pharmacology 2011;67(11):1189-98.
2011: Emmanuelle Bondon-Guitton; C Brefel; Santiago Perez Lloret; Olivier Rascol; Haleh Bagheri; Jean-Louis Montastruc
Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.
Movement disorders : official journal of the Movement Disorder Society 2011;26(12):2226-31.
2010: Guillaume Moulis; Grégory Pugnet; Haleh Bagheri; Claire Courtellemont; Antoine Huart; Dominique Chauveau; Jacques Pourrat; Jean-Louis Montastruc
Acquired factor VIII haemophilia following influenza vaccination.
European journal of clinical pharmacology 2010;66(10):1069-70.
2010: Leila Chebane; Neda Tavassoli; Haleh Bagheri; Jean-Louis Montastruc
[Drug-induced hyperglycemia: a study in the French pharmacovigilance database].
Thérapie 2010;65(5):447-58.
2010: Mireille Gony; Kattalin Badie; Agnès Sommet; Julien Jacquot; Dominique Baudrin; Pierre Gauthier; Jean Louis Montastruc; Haleh Bagheri
Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.
Drug safety : an international journal of medical toxicology and drug experience 2010;33(5):409-16.
2009: Gregory Pugnet; Loïc Ysebaert; Haleh Bagheri; Jean-Louis Montastruc; Guy Laurent
Immune thrombocytopenic purpura following human papillomavirus vaccination.
Vaccine 2009;27(28):3690.
2009: Franck Burgan; Jean-Louis Montastruc; Haleh Bagheri
[Dobesilate-induced serious neutropenia].
Presse médicale (Paris, France : 1983) 2009;38(5):846-8.
2009: G Espinasse; N Kamar; C Hurault; B Suc; G Fourtanier; Jean-Louis Montastruc; L Rostaing; Haleh Bagheri
Drug exposure and perceived adverse drug events reported by liver-transplant patients.
International journal of clinical pharmacology and therapeutics 2009;47(3):159-64.
2008: Agnès Sommet; S Grolleau; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
European journal of clinical pharmacology 2008;64(8):829-34.
2008: Agnès Sommet; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Did thirst-blockers contribute to the exorbitant number of fatalities during the French 2003 heat wave?
Pharmacoepidemiology and drug safety 2008;17(3):312-3.
2007: Geneviève Durrieu; Pascale Olivier; Haleh Bagheri; Jean-Louis Montastruc
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database.
Fundamental & clinical pharmacology 2007;21(5):555-8.
2007: Neda Tavassoli; Eliane Duchayne; B Sadaba; Karine Desboeuf; Agnès Sommet; Maryse Lapeyre-Mestre; M J Muoz; P Sie; J Honorato; Jean-Louis Montastruc; Haleh Bagheri
Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals.
European journal of clinical pharmacology 2007;63(3):221-8.
2007: Neda Tavassoli; Agnès Sommet; Maryse Lapeyre-Mestre; Haleh Bagheri; Jean-Louis Montrastruc
Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
Drug safety : an international journal of medical toxicology and drug experience 2007;30(11):1063-71.
2006: Jean-Louis Montastruc; Agnès Sommet; Isabelle Lacroix; Pascale Olivier; Geneviève Durrieu; Christine Damase-Michel; Maryse Lapeyre-Mestre; Haleh Bagheri
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
Joint, bone, spine : revue du rhumatisme 2006;73(6):629-32.
2006: P Noize; M Sauer; P Bruneval; M Moreau; Atul Pathak; Haleh Bagheri; Jean-Louis Montastruc
Valvular heart disease in a patient taking benfluorex.
Fundamental & clinical pharmacology 2006;20(6):577-8.
2006: F Michenot; Agnès Sommet; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
Pharmacoepidemiology and drug safety 2006;15(10):735-40.
2006: E Guitton; Karl Barange; Haleh Bagheri; Jean-Louis Montastruc; Jean-Pierre Vinel; S Claeyssens; Eric Bonnet; Patrice Massip
Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient.
Infection 2006;34(3):183-5.
2006: Magalie Baudrant; Haleh Bagheri; Lise Cuzin; Agnès Sommet; Valérie Bassoua; Emmanuelle Guitton; Eric Bonnet; Daniel Garipuy; Françoise Lucas; Christian Aquilina; Jean-Louis Montastruc; Patrice Massip
[Analysis of antiretroviral drugs-induced adverse effects].
Thérapie 2006;61(2):171-6.
2006: Neda Tavassoli; Haleh Bagheri; Agnès Sommet; Cyrille Delpierre; Fabrice Marion-Latard; Patrice Massip; Christian Aquilina; Eric Bonnet; Martine Obadia; Eric Labau; Jean-Louis Montastruc; Jacques Bernard
Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
Pharmacotherapy 2006;26(2):154-61.
2006: Jean-Louis Montastruc; Agnès Sommet; Pascale Olivier; Haleh Bagheri; Mireille Gony; Maryse Lapeyre-Mestre; Christine Brefel-Courbon; Joachim Ferreira; Laurent Schmitt; Jean-Michel Senard; Olivier Rascol
[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance].
Thérapie 2006;61(1):29-38.
2005: Neda Tavassoli; Haleh Bagheri; Laurent Sailler; Philippe Benkemoun; Jean-Louis Montastruc; Philippe Arlet
Estimation of time devoted to adverse drug reactions assessment in an internal medicine department.
British journal of clinical pharmacology 2005;60(4):452-3.
2005: Agnès Sommet; Cécile Azaïs-Vuillemin; Haleh Bagheri; Olivier Rascol; Jean-Louis Montastruc
Trimetazidine: a new cause for drug-induced parkinsonism?
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):1080-1.
2005: Haleh Bagheri; Mireille Gony; Jean-Louis Montastruc
[Meningococcal serogroup C vaccine: a pharmacovigilance point of view].
Thérapie 2005;60(3):287-94.
2005: Jean-Louis Montastruc; Haleh Bagheri; Isabelle Lacroix; Pascale Olivier; Geneviève Durrieu; Christine Damase-Michel; Maryse Lapeyre-Mestre
[New methods for studying drug associated risk: experience of the Toulouse Regional Pharmacovigilance Center].
Bulletin de l'Académie nationale de médecine 2005;189(3):493-502; discussion 502-5.
2004: Haleh Bagheri; Atoussa Fouladi; Karl Barange; Maryse Lapeyre-Mestre; Jean-Louis Payen; Jean-Louis Montastruc; Jean-Pierre Vinel
Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy.
Pharmacotherapy 2004;24(11):1546-53.
2004: A Dugué; Haleh Bagheri; Maryse Lapeyre-Mestre; J F Tournamille; L Sailler; G Dedieu; R Salvayre; Jean-Paul Thouvenot; P Massip; Jean-Louis Montastruc
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.
European journal of clinical pharmacology 2004;60(4):285-92.
2004: Isabelle Lacroix; Maryse Lapeyre-Mestre; Haleh Bagheri; Atul Pathak; Jean-Louis Montastruc
Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care.
Fundamental & clinical pharmacology 2004;18(2):201-6.
2004: Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Mireille Gony; Stephanie Lugardon; Haleh Bagheri
[Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data].
Thérapie 2004;59(2):201-5.
2003: Cendrine Cabou; Haleh Bagheri; Alain Cantagrel; Bernard Mazières; Jean-Louis Montastruc
[Retrospective analysis of adverse effects of infliximab in a hospital rheumatology service].
Thérapie 2003;58(5):457-62.
2003: Marie-Annick Oscar; Cécile Bataillon; Haleh Bagheri; Anne Le Quellec; Françoise Rolland; Jean-Louis Montastruc
[Acamprosate (Aotal): could adverse effects upset the treatment of alcohol dependence?].
Thérapie 2003;58(4):371-4.
2003: Jean-Louis Montastruc; L Schmitt; Haleh Bagheri
[Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
Revue neurologique 2003;159(4):441-3.
2003: Philippe Cestac; Haleh Bagheri; Maryse Lapeyre-Mestre; Pierre Sié; Atoussa Fouladi; Eric Maupas; Philippe Léger; Bernard Fontan; Patrice Massip; Jean-Louis Montastruc
Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
Drug safety : an international journal of medical toxicology and drug experience 2003;26(3):197-207.
2002: Vanina Bongard; S Ménard-Taché; Haleh Bagheri; K Kabiri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals.
British journal of clinical pharmacology 2002;54(4):433-6.
2002: Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Haleh Bagheri; Christine Damase-Michel
[Pharmacoepidemiology in clinical practice].
La Revue du praticien 2002;52(7):701-3.
2001: Haleh Bagheri; Maryse Lapeyre-Mestre; C Levy; Françoise Haramburu; Dominique Hillaire-Buys; Jean-Pierre Blayac; Jean-Louis Montastruc
[Inter-regional differences in dysthyroidism due to amiodarone: comparison of spontaneous notifications in Aquitaine, Midi-Pyrenees and Languedoc-Roussillon].
Thérapie 2001;56(3):301-6.
2001: Jean-Louis Montastruc; Christine Brefel-Courbon; Jean-Michel Senard; Haleh Bagheri; J Ferreira; Olivier Rascol; Maryse Lapeyre-Mestre
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
Clinical neuropharmacology 2001;24(3):181-3.
2000: Haleh Bagheri; F Michel; Maryse Lapeyre-Mestre; E Lagier; Jean P Cambus; Pierre Valdiguié; Jean-Louis Montastruc
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals.
British journal of clinical pharmacology 2000;50(5):479-84.
2000: Jean-Louis Montastruc; C Chaumerliac; Karine Desboeuf; M Manika; Haleh Bagheri; Olivier Rascol; Maryse Lapeyre-Mestre
Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.
Clinical neuropharmacology 2000;23(5):271-5.
2000: E Lazartigues; Christine Brefel-Courbon; Haleh Bagheri; S Costes; C Gharib; Marie-Antoinette Tran; Jean-Michel Senard; Jean-Louis Montastruc
Fluoxetine-induced pressor response in freely moving rats: a role for vasopressin and sympathetic tone.
Fundamental & clinical pharmacology 2000;14(5):443-51.
2000: N Rémy; Maryse Lapeyre-Mestre; Marie-Pierre Bareille; Haleh Bagheri; Jean-Louis Montastruc
[Drug interactions: a prospective pilot study in primary health care].
Thérapie 2000;55(3):395-8.
2000: V Pelagatti; Haleh Bagheri; P Fernandez; N Railhac; C Bregeon; Jean-Jacques Railhac; Jean-Louis Montastruc
[Adverse effects of contrast media: results of a 6 months study].
Thérapie 2000;55(3):391-4.
1999: Haleh Bagheri; Christine Damase-Michel; Maryse Lapeyre-Mestre; Sylvie CISMONDO; Damian O'Connell; Jean-Michel Senard; Olivier Rascol; Jean-Louis Montastruc
A study of salivary secretion in Parkinson's disease.
Clinical neuropharmacology 1999;22(4):213-5.
1999: Jean-Louis Montastruc; Haleh Bagheri; Maryse Lapeyre-Mestre; J M Senard
[Pharmacological vigilance and pharmacological epidemiology: principles, definition, methods and current trends in neurology].
Revue neurologique 1999;155(4):312-24.
1999: Haleh Bagheri; Sylvie CISMONDO; Jean-Louis Montastruc
[Drug-induced hiccup: a review of the France pharmacologic vigilance database].
Thérapie 1999;54(1):35-9.
1998: Haleh Bagheri; Pierre Broué; Isabelle Lacroix; D Larrey; Jean-Pierre Olives; P Vaysse; J Ghisolfi; Jean-Louis Montastruc
Fulminant hepatic failure after herbal medicine ingestion in children.
Thérapie 1998;53(1):82-3.
1997: Haleh Bagheri; Laurent Schmitt; Michel Berlan; Jean-Louis Montastruc
A comparative study of the effects of yohimbine and anetholtrithione on salivary secretion in depressed patients treated with psychotropic drugs.
European journal of clinical pharmacology 1997;52(5):339-42.
1996: C Riotte; P Duchesne; Maryse Lapeyre-Mestre; A M Pezous; Haleh Bagheri; Christine Damase-Michel; Laurent Schmitt; Jean-Louis Montastruc
[Pharmacoepidemiological study of methadone in a center of addiction management: adverse effects and combined drug consumption].
Thérapie 1996;51(5):557-9.
1996: Haleh Bagheri; M E Galian; D Bastie; A L Couffignal; Jean-André Mathieu Tafani; C Fourcade; I Morena; R Guiraud; Jean-Louis Montastruc
[Prospective survey on adverse effects of radiopharmaceuticals].
Thérapie 1996;51(5):550-3.
1996: J P Lemozit; G P De La Rhodiere; Maryse Lapeyre-Mestre; Haleh Bagheri; Jean-Louis Montastruc
A comparative study of adverse drug reactions reported through hospital and private medicine.
British journal of clinical pharmacology 1996;41(2):166-8.
1995: P Pouget-Zago; Maryse Lapeyre-Mestre; Haleh Bagheri; Jean-Louis Montastruc
[Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region].
Thérapie 1995;50(5):459-62.
1995: K Sacilotto; Haleh Bagheri; Maryse Lapeyre-Mestre; Jean-Louis Montastruc; P Montastruc
[Adverse drug effect notifications by nurses and comparison with cases reported by physicians].
Thérapie 1995;50(5):455-8.
1995: Haleh Bagheri; J J Chale; L N Guyen; Marie-Antoinette Tran; Michel Berlan; Jean-Louis Montastruc
Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha 2-adrenoceptor antagonist.
Fundamental & clinical pharmacology 1995;9(3):248-54.
1994: Haleh Bagheri; Michel Berlan; Jean-Michel Senard; Olivier Rascol; Jean-Louis Montastruc
Lacrimation in Parkinson's disease.
Clinical neuropharmacology 1994;17(1):89-91.
1994: Haleh Bagheri; P Picault; Laurent Schmitt; G Houin; Michel Berlan; Jean-Louis Montastruc
Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.
British journal of clinical pharmacology 1994;37(1):93-6.
1992: Haleh Bagheri; Laurent Schmitt; Michel Berlan; Jean-Louis Montastruc
Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.
British journal of clinical pharmacology 1992;34(6):555-8.
1992: Christine Damase-Michel; G Tavernier; M E Llau; François Chollet; Jean-Michel Sénard; Haleh Bagheri; Marie-Antoinette Tran; G Houin; Bernard Guiraud-Chaumeil; Jean-Louis Montastruc
[Is there any desensitization of presynaptic alpha 2-adrenergic receptors in hypertension? Experimental and clinical studies].
Archives des maladies du coeur et des vaisseaux 1992;85(8):1149-51.
1991: Christine Damase-Michel; L Schmitt; B Le Quang; Haleh Bagheri; Jean-Louis Montastruc; P Moron
Plasma dopamine-beta-hydroxylase activity in depressed patients: role of treatment.
Journal of neurology, neurosurgery, and psychiatry 1991;54(8):749.